PTD-DBM

PTD-DBM is a therapeutic peptide primarily used to treat various forms of hair loss.

Its amino acid sequence was derived from a deep understanding of the pathophysiology of androgenetic alopecia, along with the subsequent discovery and application of cell-penetrating peptides (CPPs).

Multiple arginine-rich sequences are incorporated within PTD-DBM, conferring upon it potent cell-penetrating capabilities.

Covalent linkage (via a glycine linker) to a defined bioactive DBM peptide segment gives the full peptide dual functional properties.

The poly-arginine sequence at the N-terminus allows effective penetration of both the skin’s stratum corneum and all subsequent cell membranes; precise delivery of the active cargo to dermal papilla cells (and associated stem cell niches) is achieved.

The discovery and synthesis of PTD-DBM represents a significant shift in hair loss treatment – moving from systemic or simple vasodilatory effects, to precise microenvironmental and regenerative repair of the hair follicle itself.

Sequence

Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys

CAS Number

1609454-11-6

Molecular Formula

C124H225N61O28S2

Molecular Weight

3082.683

PTD-DBM Peptide Related Research

The carboxyl-terminal DBM part acts as a specific molecular trap, capturing excess BMP molecules – intracellularly and extracellularly – neutralizing them.

Direct downstream growth inhibitory signaling is thereby blocked.

DBM relieves this inhibition, prolonging the anagen phase (growth) and preventing premature catagen/telogen transitions.

Potent anti-hair loss effects result: thicker, more resilient hair is produced.

Secondly, reactivation of dormant hair follicle stem cells is observed, with promotion of their proliferation and differentiation into new hair follicle progenitors being supported.

Specifically, BMPs are the primary inhibitory signals to hair growth; PTD-DBM binds to and prevents activation of these signals, and so all of the above mentioned effects follow as a direct result of its action.

During the normal hair growth cycle, anagen (the growth phase) is succeeded by catagen (a form of regression).

Bone morphogenetic proteins (BMPs) signaling plays a significant role in shortening this anagen phase; premature entry into telogen, the true resting phase, is the direct result.

Finer, shorter, less pigmented hair follows in subsequent cycles.

PTD-DBM acts to block this specific signaling pathway.

Prolonging the active phase is one of its primary mechanisms of action.

Continued production of thicker more healthy hair is possible; halting the pathological process of hair loss itself is the end point the compound aims to achieve.

Hair density is thereby preserved.